FAP (F11-24) Antibody from Santa Cruz Biotechnology, Inc.

The FAP (F11-24) Antibody has been shown to work in applications such as flow cytometry, immunofluorescence, and immunoprecipitation. For instance, it has been utilized in immunofluorescence staining to analyze fibroblast activation in various cancer models, including ovarian and pancreatic cancers.

Yes, the FAP antibody has been cited in multiple studies highlighting its significance in cancer research. For example, it has been used to investigate the role of fibroblast activation protein in promoting tumor progression and metastasis in ovarian cancer, as well as its correlation with poor prognosis in pancreatic adenocarcinoma.

The FAP antibody has been employed to study the interactions between tumor cells and activated fibroblasts, particularly in the context of signaling pathways that promote cancer cell migration and invasion. Research has demonstrated that FAP expression is associated with the activation of pathways that enhance tumor aggressiveness, such as the TNF-α/IL-33 signaling in gastric cancer.

Studies have shown that the FAP antibody can be used to identify activated fibroblasts in tumor stroma, which are crucial for understanding the fibrotic response in cancers. For instance, it has been reported that FAP expression is significantly higher in advanced stages of ovarian cancer and correlates with the activation of pro-tumorigenic signaling pathways, thereby influencing cancer cell survival and metastasis.